Free Trial

Sage Therapeutics (SAGE) Financials

Sage Therapeutics logo
$7.43 +0.06 (+0.81%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$7.42 -0.01 (-0.20%)
As of 04/17/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Sage Therapeutics

Annual Income Statements for Sage Therapeutics

This table shows Sage Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-533 -541 -401
Consolidated Net Income / (Loss)
-533 -541 -401
Net Income / (Loss) Continuing Operations
-533 -541 -401
Total Pre-Tax Income
-533 -541 -401
Total Operating Income
-547 -580 -432
Total Gross Profit
7.69 86 41
Total Revenue
7.69 86 41
Operating Revenue
7.69 86 41
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
555 666 474
Selling, General & Admin Expense
228 275 216
Research & Development Expense
326 356 226
Other Operating Expenses / (Income)
0.81 2.16 9.44
Restructuring Charge
0.00 33 22
Total Other Income / (Expense), net
14 38 32
Interest & Investment Income
14 39 32
Other Income / (Expense), net
- -0.38 0.03
Basic Earnings per Share
($8.98) ($9.05) ($6.59)
Weighted Average Basic Shares Outstanding
59.31M 59.84M 60.77M
Diluted Earnings per Share
($8.98) ($9.05) ($6.59)
Weighted Average Diluted Shares Outstanding
59.31M 59.84M 60.77M
Weighted Average Basic & Diluted Shares Outstanding
59.72M 60.11M 61.48M

Quarterly Income Statements for Sage Therapeutics

This table shows Sage Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-137 -147 -147 -160 -202 -33 -108 -103 -94 -96
Consolidated Net Income / (Loss)
-137 -147 -147 -160 -202 -33 -108 -103 -94 -96
Net Income / (Loss) Continuing Operations
-137 -147 -147 -160 -202 -33 -108 -103 -94 -96
Total Pre-Tax Income
-137 -147 -147 -160 -202 -33 -108 -103 -94 -96
Total Operating Income
-141 -154 -155 -170 -212 -42 -118 -111 -101 -102
Total Gross Profit
1.56 3.53 3.06 2.27 2.72 78 6.63 8.65 6.59 19
Total Revenue
1.74 2.86 3.29 2.47 2.72 78 7.90 8.65 12 13
Operating Revenue
1.74 2.86 3.29 2.47 2.72 78 7.90 8.65 12 13
Total Cost of Revenue
0.18 -0.67 0.23 0.21 0.00 -0.44 1.27 0.00 5.28 -6.55
Total Operating Expenses
143 157 159 173 215 120 124 120 108 122
Selling, General & Admin Expense
61 67 66 76 78 55 53 56 53 55
Research & Development Expense
82 89 93 97 102 64 72 63 55 37
Total Other Income / (Expense), net
4.16 6.76 8.83 10 10 9.08 9.20 8.43 7.64 6.43
Interest & Investment Income
4.13 6.79 8.83 10 10 9.47 9.20 8.43 7.64 6.40
Basic Earnings per Share
($2.31) ($2.47) ($2.46) ($2.68) ($3.37) ($0.54) ($1.80) ($1.70) ($1.53) ($1.56)
Weighted Average Basic Shares Outstanding
59.43M 59.31M 59.67M 59.77M 59.91M 59.84M 60.14M 60.54M 61.12M 60.77M
Diluted Earnings per Share
($2.31) ($2.47) ($2.46) ($2.68) ($3.37) ($0.54) ($1.80) ($1.70) ($1.53) ($1.56)
Weighted Average Diluted Shares Outstanding
59.43M 59.31M 59.67M 59.77M 59.91M 59.84M 60.14M 60.54M 61.12M 60.77M
Weighted Average Basic & Diluted Shares Outstanding
59.49M 59.72M 59.76M 59.88M 59.97M 60.11M 60.18M 61.05M 61.17M 61.48M

Annual Cash Flow Statements for Sage Therapeutics

This table details how cash moves in and out of Sage Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-132 -92 10
Net Cash From Operating Activities
-460 -541 -267
Net Cash From Continuing Operating Activities
-460 -541 -267
Net Income / (Loss) Continuing Operations
-533 -541 -401
Consolidated Net Income / (Loss)
-533 -541 -401
Depreciation Expense
1.12 1.39 1.03
Amortization Expense
5.85 -6.34 -6.48
Non-Cash Adjustments To Reconcile Net Income
66 79 59
Changes in Operating Assets and Liabilities, net
0.09 -73 79
Net Cash From Investing Activities
325 443 267
Net Cash From Continuing Investing Activities
325 443 267
Purchase of Property, Plant & Equipment
-0.94 -0.55 0.00
Purchase of Investments
-881 -595 -451
Sale and/or Maturity of Investments
1,207 1,038 718
Net Cash From Financing Activities
3.07 6.03 11
Net Cash From Continuing Financing Activities
3.07 6.03 11
Repurchase of Common Equity
0.00 0.00 -0.12
Issuance of Common Equity
3.11 6.93 11
Other Financing Activities, net
-0.04 -0.90 -0.40

Quarterly Cash Flow Statements for Sage Therapeutics

This table details how cash moves in and out of Sage Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-6.68 -37 44 -85 27 -78 103 -73 -0.27 -20
Net Cash From Operating Activities
-119 -127 -154 -132 -136 -120 -38 -80 -82 -67
Net Cash From Continuing Operating Activities
-119 -127 -154 -132 -136 -120 -38 -80 -82 -67
Net Income / (Loss) Continuing Operations
-137 -147 -147 -160 -202 -33 -108 -103 -94 -96
Consolidated Net Income / (Loss)
-137 -147 -147 -160 -202 -33 -108 -103 -94 -96
Depreciation Expense
0.28 0.29 0.32 0.33 0.33 0.41 0.34 0.31 0.26 0.13
Amortization Expense
1.07 -1.33 -3.18 -4.39 -4.95 6.18 -1.55 -1.94 -2.05 -0.94
Non-Cash Adjustments To Reconcile Net Income
15 17 21 13 30 14 15 19 16 9.90
Changes in Operating Assets and Liabilities, net
2.54 4.61 -25 20 40 -108 57 5.35 -2.62 20
Net Cash From Investing Activities
111 90 195 46 160 42 139 -0.39 81 47
Net Cash From Continuing Investing Activities
111 90 195 46 160 42 139 -0.39 81 47
Purchase of Investments
-251 -199 -157 -233 -70 -135 -62 -198 -102 -89
Sale and/or Maturity of Investments
363 289 352 278 231 177 201 198 183 135
Net Cash From Financing Activities
1.23 0.03 2.67 0.85 2.77 -0.26 1.56 8.07 1.04 -0.00
Net Cash From Continuing Financing Activities
1.23 0.03 2.67 0.85 2.77 -0.26 1.56 8.07 1.04 -0.00
Issuance of Common Equity
1.24 0.03 3.30 0.86 2.77 - 1.56 8.19 1.44 -0.00
Other Financing Activities, net
-0.02 -0.00 -0.63 -0.01 -0.00 -0.26 -0.00 -0.00 -0.40 -0.00

Annual Balance Sheets for Sage Therapeutics

This table presents Sage Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
1,356 882 547
Total Current Assets
1,337 869 531
Cash & Equivalents
163 71 81
Restricted Cash
0.00 1.33 0.00
Short-Term Investments
1,110 682 423
Accounts Receivable
14 83 9.13
Prepaid Expenses
51 32 18
Plant, Property, & Equipment, net
2.90 1.92 0.89
Total Noncurrent Assets
17 11 15
Other Noncurrent Operating Assets
15 11 14
Other Noncurrent Nonoperating Assets
1.27 0.00 1.45
Total Liabilities & Shareholders' Equity
1,356 882 547
Total Liabilities
104 83 82
Total Current Liabilities
99 83 72
Accounts Payable
19 10 13
Accrued Expenses
73 67 58
Other Current Liabilities
7.64 5.17 1.32
Total Noncurrent Liabilities
4.59 0.00 11
Other Noncurrent Operating Liabilities
4.59 0.00 11
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,253 800 465
Total Preferred & Common Equity
1,253 800 465
Preferred Stock
0.00 0.00 0.00
Total Common Equity
1,253 800 465
Common Stock
3,291 3,370 3,436
Retained Earnings
-2,028 -2,570 -2,970
Treasury Stock
-0.40 -0.40 -0.40
Accumulated Other Comprehensive Income / (Loss)
-10 -0.81 0.24

Quarterly Balance Sheets for Sage Therapeutics

This table presents Sage Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,486 1,221 1,082 950 768 697 622
Total Current Assets
1,465 1,203 1,064 933 755 687 605
Cash & Equivalents
200 207 121 149 173 100 100
Restricted Cash
- - - - 1.33 1.33 1.33
Short-Term Investments
1,194 923 881 727 544 547 470
Accounts Receivable
18 15 15 23 11 9.94 15
Prepaid Expenses
53 59 46 35 27 29 20
Plant, Property, & Equipment, net
2.82 2.66 2.48 2.44 1.59 1.27 1.02
Total Noncurrent Assets
18 15 16 14 11 9.02 16
Other Noncurrent Operating Assets
17 13 14 13 9.07 9.02 16
Other Noncurrent Nonoperating Assets
1.27 1.27 1.33 1.33 1.50 0.00 0.00
Total Liabilities & Shareholders' Equity
1,486 1,221 1,082 950 768 697 622
Total Liabilities
106 88 98 133 62 69 71
Total Current Liabilities
100 85 97 133 62 69 60
Accounts Payable
7.08 12 9.28 11 6.48 8.65 7.13
Accrued Expenses
85 65 80 115 52 59 53
Other Current Liabilities
7.60 7.68 7.73 6.97 3.31 1.41 0.08
Total Noncurrent Liabilities
6.26 2.87 1.11 0.00 0.00 0.00 10
Other Noncurrent Operating Liabilities
6.26 2.87 1.11 0.00 - - 10
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,380 1,133 984 817 706 628 552
Total Preferred & Common Equity
1,380 1,133 984 817 706 628 552
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,380 1,133 984 817 706 628 552
Common Stock
3,276 3,314 3,326 3,358 3,385 3,410 3,426
Retained Earnings
-1,881 -2,175 -2,335 -2,537 -2,678 -2,781 -2,875
Treasury Stock
-0.40 -0.40 -0.40 -0.40 -0.40 -0.40 -0.40
Accumulated Other Comprehensive Income / (Loss)
-15 -5.09 -5.64 -3.74 -0.79 -0.69 0.90

Annual Metrics and Ratios for Sage Therapeutics

This table displays calculated financial ratios and metrics derived from Sage Therapeutics' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
21.85% 1,024.84% -52.30%
EBITDA Growth
-21.71% -8.36% 25.19%
EBIT Growth
-18.68% -6.08% 25.49%
NOPAT Growth
-18.68% -6.01% 25.43%
Net Income Growth
-16.36% -1.63% 26.01%
EPS Growth
-15.13% -0.78% 27.18%
Operating Cash Flow Growth
-21.64% -17.51% 50.57%
Free Cash Flow Firm Growth
-11.64% -25.46% 54.06%
Invested Capital Growth
-45.62% 312.69% -190.59%
Revenue Q/Q Growth
18.90% 661.85% -61.24%
EBITDA Q/Q Growth
-6.74% 16.91% -18.23%
EBIT Q/Q Growth
-5.48% 16.11% -16.14%
NOPAT Q/Q Growth
-5.48% 16.17% -16.15%
Net Income Q/Q Growth
-4.40% 17.45% -18.68%
EPS Q/Q Growth
-4.06% 17.58% -18.31%
Operating Cash Flow Q/Q Growth
-6.83% 1.35% 16.54%
Free Cash Flow Firm Q/Q Growth
-5.40% -7.72% 28.34%
Invested Capital Q/Q Growth
-43.14% 174.13% -118.64%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-7,025.94% -676.86% -1,061.49%
Operating Margin
-7,116.69% -670.69% -1,048.35%
EBIT Margin
-7,116.69% -671.14% -1,048.28%
Profit (Net Income) Margin
-6,931.88% -626.32% -971.48%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
97.41% 93.32% 92.67%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -3,403.73% -14,293.22%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -3,390.36% -14,277.67%
Return on Net Nonoperating Assets (RNNOA)
0.00% 3,350.95% 14,229.86%
Return on Equity (ROE)
-35.74% -52.77% -63.37%
Cash Return on Invested Capital (CROIC)
0.00% -1,048.72% 0.00%
Operating Return on Assets (OROA)
-34.38% -51.84% -60.49%
Return on Assets (ROA)
-33.49% -48.37% -56.06%
Return on Common Equity (ROCE)
-35.74% -52.77% -63.37%
Return on Equity Simple (ROE_SIMPLE)
-42.53% -67.73% -86.15%
Net Operating Profit after Tax (NOPAT)
-383 -406 -303
NOPAT Margin
-4,981.68% -469.49% -733.84%
Net Nonoperating Expense Percent (NNEP)
-9.94% -13.37% -15.55%
Return On Investment Capital (ROIC_SIMPLE)
-30.57% -50.77% -65.08%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
2,962.52% 317.53% 524.74%
R&D to Revenue
4,243.60% 412.05% 547.72%
Operating Expenses to Revenue
7,216.69% 770.69% 1,148.35%
Earnings before Interest and Taxes (EBIT)
-547 -580 -432
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-540 -585 -438
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.81 1.63 0.71
Price to Tangible Book Value (P/TBV)
1.81 1.63 0.71
Price to Revenue (P/Rev)
295.22 15.03 8.05
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 12.11 0.00
Enterprise Value to Revenue (EV/Rev)
129.66 6.30 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.01 -0.99 -1.00
Leverage Ratio
1.07 1.09 1.13
Compound Leverage Factor
1.04 1.02 1.05
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
10.79 4.34 -6.70
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
13.47 10.51 7.42
Quick Ratio
12.96 10.11 7.17
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-376 -472 -217
Operating Cash Flow to CapEx
-49,096.69% -97,754.97% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.08 0.06
Accounts Receivable Turnover
0.48 1.79 0.90
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
2.60 35.88 29.34
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
763.76 204.06 407.73
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
763.76 204.06 407.73
Capital & Investment Metrics
- - -
Invested Capital
-21 45 -41
Invested Capital Turnover
-0.43 7.25 19.48
Increase / (Decrease) in Invested Capital
-6.63 66 -86
Enterprise Value (EV)
997 545 -172
Market Capitalization
2,269 1,299 332
Book Value per Share
$21.05 $13.33 $7.60
Tangible Book Value per Share
$21.05 $13.33 $7.60
Total Capital
1,253 800 465
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-1,272 -755 -504
Capital Expenditures (CapEx)
0.94 0.55 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-35 32 -45
Debt-free Net Working Capital (DFNWC)
1,238 787 460
Net Working Capital (NWC)
1,238 787 460
Net Nonoperating Expense (NNE)
150 136 98
Net Nonoperating Obligations (NNO)
-1,274 -755 -506
Total Depreciation and Amortization (D&A)
6.98 -4.95 -5.45
Debt-free, Cash-free Net Working Capital to Revenue
-452.42% 37.11% -108.46%
Debt-free Net Working Capital to Revenue
16,103.58% 909.84% 1,114.58%
Net Working Capital to Revenue
16,103.58% 909.84% 1,114.58%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($8.98) ($9.05) ($6.59)
Adjusted Weighted Average Basic Shares Outstanding
59.31M 59.84M 60.77M
Adjusted Diluted Earnings per Share
($8.98) ($9.05) ($6.59)
Adjusted Weighted Average Diluted Shares Outstanding
59.31M 59.84M 60.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
59.72M 60.11M 61.48M
Normalized Net Operating Profit after Tax (NOPAT)
-383 -383 -287
Normalized NOPAT Margin
-4,981.68% -442.45% -696.75%
Pre Tax Income Margin
-6,932.07% -626.32% -971.48%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -0.03%

Quarterly Metrics and Ratios for Sage Therapeutics

This table displays calculated financial ratios and metrics derived from Sage Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
20.76% 74.42% 108.22% 64.82% 56.18% 2,622.45% 139.89% 249.80% 337.08% -83.56%
EBITDA Growth
-10.77% -28.23% -32.61% -39.01% -54.51% 77.10% 24.91% 35.29% 52.42% -190.30%
EBIT Growth
-8.06% -22.64% -26.19% -32.75% -49.77% 72.66% 24.31% 34.70% 52.23% -142.89%
NOPAT Growth
-8.09% -22.64% -26.19% -32.75% -49.74% 72.66% 24.31% 34.70% 52.23% -142.89%
Net Income Growth
-5.49% -17.99% -20.30% -26.98% -46.83% 77.77% 26.12% 35.85% 53.60% -192.85%
EPS Growth
-4.52% -16.51% -18.84% -25.82% -45.89% 78.14% 26.83% 36.57% 54.60% -188.89%
Operating Cash Flow Growth
-72.70% -30.19% -42.56% -23.56% -14.30% 5.84% 75.38% 38.84% 39.38% 44.31%
Free Cash Flow Firm Growth
3.26% 1.11% -48.44% -46.66% -10.02% 5.41% 44.55% 24.61% -10.32% 114.91%
Invested Capital Growth
-68.33% -45.62% 128.41% -565.71% -310.69% 312.69% -717.32% -2.51% 69.29% -190.59%
Revenue Q/Q Growth
15.86% 64.69% 15.01% -24.89% 9.78% 2,770.80% -89.87% 9.52% 37.17% 7.96%
EBITDA Q/Q Growth
-11.59% -10.59% -2.18% -10.23% -24.04% 83.61% -235.07% 5.02% 8.80% -0.01%
EBIT Q/Q Growth
-10.16% -8.80% -1.02% -9.64% -24.28% 80.14% -179.69% 5.42% 9.07% -0.98%
NOPAT Q/Q Growth
-10.18% -8.78% -1.02% -9.64% -24.28% 80.14% -179.69% 5.42% 9.07% -0.98%
Net Income Q/Q Growth
-8.76% -7.15% 0.22% -9.19% -25.76% 83.78% -231.69% 5.19% 9.04% -2.38%
EPS Q/Q Growth
-8.45% -6.93% 0.40% -8.94% -25.75% 83.98% -233.33% 5.56% 10.00% -1.96%
Operating Cash Flow Q/Q Growth
-11.67% -6.79% -21.07% 14.42% -3.31% 12.03% 68.35% -112.62% -2.40% 19.19%
Free Cash Flow Firm Q/Q Growth
-32.87% -8.67% -17.81% 13.79% 0.32% 6.57% 30.93% -17.21% -45.85% 112.63%
Invested Capital Q/Q Growth
-402.93% -43.14% 110.75% -960.31% -210.26% 174.13% -131.20% -42.86% 7.04% -118.64%
Profitability Metrics
- - - - - - - - - -
Gross Margin
89.42% 123.39% 93.02% 91.71% 100.00% 100.56% 83.94% 100.00% 55.54% 151.08%
EBITDA Margin
-8,056.58% -5,409.99% -4,806.50% -7,054.04% -7,970.18% -45.51% -1,504.59% -1,304.90% -867.61% -803.74%
Operating Margin
-8,135.71% -5,373.71% -4,719.79% -6,889.94% -7,800.04% -53.96% -1,489.18% -1,286.11% -852.51% -797.39%
EBIT Margin
-8,133.99% -5,373.71% -4,719.79% -6,889.94% -7,800.04% -53.96% -1,489.18% -1,286.11% -852.51% -797.39%
Profit (Net Income) Margin
-7,896.66% -5,137.78% -4,457.44% -6,480.40% -7,423.79% -41.95% -1,372.86% -1,188.51% -788.06% -747.33%
Tax Burden Percent
100.00% 100.00% 100.13% 100.03% 100.03% 99.14% 100.01% 99.99% 99.99% 100.01%
Interest Burden Percent
97.08% 95.61% 94.32% 94.03% 95.15% 78.41% 92.18% 92.43% 92.45% 93.71%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -273.84% 0.00% 0.00% 0.00% -10,871.60%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -273.52% 0.00% 0.00% 0.00% -10,867.75%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 270.34% 0.00% 0.00% 0.00% 10,831.36%
Return on Equity (ROE)
-31.74% -35.74% -40.53% -47.55% -59.72% -3.50% -54.72% -55.28% -49.34% -40.24%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -18,275.38% 0.00% 0.00% -1,048.72% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-30.81% -25.96% -30.31% -53.25% -72.68% -4.17% -136.41% -140.57% -115.39% -46.01%
Return on Assets (ROA)
-29.91% -24.82% -28.63% -50.09% -69.17% -3.24% -125.75% -129.90% -106.67% -43.12%
Return on Common Equity (ROCE)
-31.74% -35.74% -40.53% -47.55% -59.72% -3.50% -54.72% -55.28% -49.34% -40.24%
Return on Equity Simple (ROE_SIMPLE)
-36.98% 0.00% -49.21% -60.10% -80.32% 0.00% -71.29% -70.96% -61.18% 0.00%
Net Operating Profit after Tax (NOPAT)
-99 -108 -109 -119 -148 -29 -82 -78 -71 -72
NOPAT Margin
-5,695.00% -3,761.60% -3,303.86% -4,822.95% -5,460.03% -37.77% -1,042.43% -900.28% -596.76% -558.17%
Net Nonoperating Expense Percent (NNEP)
-2.36% -2.61% -2.76% -3.27% -4.69% -0.32% -2.82% -3.02% -3.14% -3.85%
Return On Investment Capital (ROIC_SIMPLE)
- -8.60% - - - -3.68% - - - -15.38%
Cost of Revenue to Revenue
10.58% -23.39% 6.98% 8.29% 0.00% -0.56% 16.06% 0.00% 44.46% -51.08%
SG&A Expenses to Revenue
3,535.48% 2,350.87% 1,994.78% 3,054.37% 2,877.10% 70.68% 665.33% 646.90% 448.31% 426.37%
R&D to Revenue
4,689.65% 3,117.84% 2,818.03% 3,927.28% 3,752.54% 82.50% 907.80% 722.95% 459.74% 288.87%
Operating Expenses to Revenue
8,225.13% 5,497.10% 4,812.81% 6,981.65% 7,900.04% 154.52% 1,573.12% 1,386.11% 908.05% 948.47%
Earnings before Interest and Taxes (EBIT)
-141 -154 -155 -170 -212 -42 -118 -111 -101 -102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-140 -155 -158 -175 -216 -35 -119 -113 -103 -103
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.69 1.81 2.21 2.85 1.51 1.63 1.59 1.04 0.80 0.71
Price to Tangible Book Value (P/TBV)
1.69 1.81 2.21 2.85 1.51 1.63 1.59 1.04 0.80 0.71
Price to Revenue (P/Rev)
359.99 295.22 266.63 270.95 108.60 15.03 12.34 6.72 4.14 8.05
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 604.91 0.00 0.00 12.11 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
144.39 129.66 146.43 174.27 31.40 6.30 4.45 0.06 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -1.01 -1.00 -1.01 -1.03 -0.99 -1.01 -1.02 -1.06 -1.00
Leverage Ratio
1.06 1.07 1.06 1.08 1.11 1.09 1.08 1.10 1.15 1.13
Compound Leverage Factor
1.03 1.02 1.00 1.01 1.06 0.86 1.00 1.02 1.06 1.06
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
12.20 11.74 15.36 14.76 2.11 6.36 6.72 0.77 -2.04 -4.71
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
14.70 13.47 14.21 10.99 7.02 10.51 12.22 9.95 10.02 7.42
Quick Ratio
14.17 12.96 13.51 10.51 6.76 10.11 11.77 9.51 9.67 7.17
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-93 -101 -119 -103 -102 -96 -66 -77 -113 14
Operating Cash Flow to CapEx
-32,655.22% -45,011.35% -68,303.11% -117,426.79% -41,422.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.01 0.01 0.01 0.08 0.09 0.11 0.14 0.06
Accounts Receivable Turnover
0.30 0.48 0.54 0.53 0.55 1.79 7.14 7.77 5.69 0.90
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
2.26 2.60 3.42 3.83 4.31 35.88 42.87 51.81 61.48 29.34
Accounts Payable Turnover
0.03 0.00 0.00 0.00 0.00 0.00 0.11 0.09 0.67 0.00
Days Sales Outstanding (DSO)
1,203.67 763.76 675.76 682.98 658.74 204.06 51.13 46.98 64.12 407.73
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
10,565.32 0.00 0.00 0.00 0.00 0.00 3,292.03 3,924.19 545.29 0.00
Cash Conversion Cycle (CCC)
-9,361.65 763.76 675.76 682.98 658.74 204.06 -3,240.90 -3,877.21 -481.17 407.73
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-15 -21 2.28 -20 -61 45 -14 -20 -19 -41
Invested Capital Turnover
-0.55 -0.43 -3.28 -0.92 -0.30 7.25 -15.48 -4.91 -2.68 19.48
Increase / (Decrease) in Invested Capital
-6.00 -6.63 10 -17 -46 66 -16 -0.49 42 -86
Enterprise Value (EV)
933 997 1,376 1,807 356 545 405 5.45 -130 -172
Market Capitalization
2,327 2,269 2,506 2,810 1,232 1,299 1,124 654 441 332
Book Value per Share
$23.23 $21.05 $18.97 $16.47 $13.64 $13.33 $11.74 $10.44 $9.04 $7.60
Tangible Book Value per Share
$23.23 $21.05 $18.97 $16.47 $13.64 $13.33 $11.74 $10.44 $9.04 $7.60
Total Capital
1,380 1,253 1,133 984 817 800 706 628 552 465
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-1,394 -1,272 -1,130 -1,003 -876 -755 -718 -648 -570 -504
Capital Expenditures (CapEx)
0.36 0.28 0.23 0.11 0.33 -0.11 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-28 -35 -11 -35 -76 32 -25 -30 -26 -45
Debt-free Net Working Capital (DFNWC)
1,365 1,238 1,119 967 800 787 694 618 545 460
Net Working Capital (NWC)
1,365 1,238 1,119 967 800 787 694 618 545 460
Net Nonoperating Expense (NNE)
38 39 38 41 53 3.25 26 25 23 24
Net Nonoperating Obligations (NNO)
-1,395 -1,274 -1,131 -1,004 -877 -755 -720 -648 -570 -506
Total Depreciation and Amortization (D&A)
1.35 -1.04 -2.86 -4.06 -4.62 6.59 -1.22 -1.63 -1.79 -0.81
Debt-free, Cash-free Net Working Capital to Revenue
-436.60% -452.42% -115.34% -341.30% -667.84% 37.11% -27.13% -31.22% -24.35% -108.46%
Debt-free Net Working Capital to Revenue
21,123.41% 16,103.58% 11,904.08% 9,326.20% 7,052.04% 909.84% 761.72% 635.28% 511.83% 1,114.58%
Net Working Capital to Revenue
21,123.41% 16,103.58% 11,904.08% 9,326.20% 7,052.04% 909.84% 761.72% 635.28% 511.83% 1,114.58%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($2.31) ($2.47) ($2.46) ($2.68) ($3.37) ($0.54) ($1.80) ($1.70) ($1.53) ($1.56)
Adjusted Weighted Average Basic Shares Outstanding
59.43M 59.31M 59.67M 59.77M 59.91M 59.84M 60.14M 60.54M 61.12M 60.77M
Adjusted Diluted Earnings per Share
($2.31) ($2.47) ($2.46) ($2.68) ($3.37) ($0.54) ($1.80) ($1.70) ($1.53) ($1.56)
Adjusted Weighted Average Diluted Shares Outstanding
59.43M 59.31M 59.67M 59.77M 59.91M 59.84M 60.14M 60.54M 61.12M 60.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
59.49M 59.72M 59.76M 59.88M 59.97M 60.11M 60.18M 61.05M 61.17M 61.48M
Normalized Net Operating Profit after Tax (NOPAT)
-99 -108 -109 -119 -125 -29 -82 -78 -71 -72
Normalized NOPAT Margin
-5,695.00% -3,761.60% -3,303.86% -4,822.95% -4,594.07% -37.77% -1,042.43% -900.28% -596.76% -558.17%
Pre Tax Income Margin
-7,896.66% -5,137.57% -4,451.73% -6,478.74% -7,421.76% -42.31% -1,372.70% -1,188.69% -788.14% -747.24%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.03% -0.03% -0.03%

Frequently Asked Questions About Sage Therapeutics' Financials

When does Sage Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Sage Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sage Therapeutics' net income changed over the last 2 years?

Sage Therapeutics' net income appears to be on a downward trend, with a most recent value of -$400.67 million in 2024, falling from -$532.78 million in 2022. The previous period was -$541.49 million in 2023.

What is Sage Therapeutics's operating income?
Sage Therapeutics's total operating income in 2024 was -$432.37 million, based on the following breakdown:
  • Total Gross Profit: $41.24 million
  • Total Operating Expenses: $473.61 million
How has Sage Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Sage Therapeutics' total revenue changed from $7.69 million in 2022 to $41.24 million in 2024, a change of 436.6%.

How much debt does Sage Therapeutics have?

Sage Therapeutics' total liabilities were at $82.13 million at the end of 2024, a 0.7% decrease from 2023, and a 20.9% decrease since 2022.

How much cash does Sage Therapeutics have?

In the past 2 years, Sage Therapeutics' cash and equivalents has ranged from $70.99 million in 2023 to $162.70 million in 2022, and is currently $81.02 million as of their latest financial filing in 2024.

How has Sage Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Sage Therapeutics' book value per share changed from 21.05 in 2022 to 7.60 in 2024, a change of -63.9%.



This page (NASDAQ:SAGE) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners